Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial - Powles, T; Csőszi, T; Özgüroğlu, M (Lancet Oncol, 2021)
et al.